Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 6/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411134 | 0.93 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL29892026 | 0.93 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL16980528 | 0.89 | HTR3A (0.65) | HTR3AHPGD | |
| SCHEMBL11437886 | 0.85 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL9931641 | 0.85 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL22996165 | 0.82 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| Hydrochloric Acid SCHEMBL11453023 | 0.80 | HTR2C (0.47) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL30228711 | 0.80 | HTR2C (0.56) | SLC18A3SIGMAR1HTR2CHTR3AQDPR | |
| SCHEMBL11984417 | 0.79 | HTR3A (0.53) | HTR3ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11213083 | 0.79 | HPGD (0.50) | SLC6A2SLC6A4SLC6A3HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024151741-A1 | MUTANT-SELECTIVE EGFR INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1610786-A1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089373-A1 | 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | SLC18A3 3704/4885SIGMAR1 1759/4885HTR2C 1269/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAK4, PAK2, PAK1 | SLC18A3 4168/4885SIGMAR1 4826/4885HTR2C 4194/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SLC18A3 4230/4885SIGMAR1 4493/4885HTR2C 4125/4885 |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | SLC18A3 3704/4885SIGMAR1 1759/4885HTR2C 1269/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | SLC18A3 2982/4885SIGMAR1 2500/4885HTR2C 2577/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | SLC18A3 3704/4885SIGMAR1 1759/4885HTR2C 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.